Amarin Corporation (AMRN)


Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Amarin Corporation To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Amarin Corporation ("Amarin" or the "Company")(NASDAQ:AMRN) of the April 23, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.


If you invested in Amarin stock or options between September 24, 2018 and November 9, 2018 and would like to discuss your legal rights, please fill out the form below. There is no cost or obligation to you. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.

The lawsuit has been filed in the U.S. District Court for the New Jersey on behalf of all those who purchased Amarin securities between September 24, 2018 and November 9, 2018 (the "Class Period"). The case, Sharma v. Amarin Corporation, PLC et al., No. 19-cv-06601 was filed on February 22, 2019, and has been assigned to Brian R. Martinotti.


The lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements regarding its REDUCE-IT study. The placebo given to patients in the study’s control arm may have increased the incidence of cardiovascular events in those patients, thus making Vascepa appear more effective than it actually was.


On November 10, 2018, scientists that conducted the REDUCE-IT trial presented the full results of that study at the Scientific Sessions of the American Heart Association in Chicago, Illinois. In that presentation, the scientists disclosed for the first time "bad" LDL cholesterol levels rose three percent in the Vascepa patients and ten percent in the placebo patients. Other markers of blood fat were also higher in the placebo patients.

On this news, Amarin's share price fell from $21.05 per share on November 9, 2018 to a closing price of $15.38 on  November 13, 2018: a $5.67 or a 26.94% drop.

Contact us

Amarin Corporation (AMRN)

Loading captcha, please wait...

* The submission of this form does not create an attorney-client relationship.

Details

Filed on 02/28/2019

Ticker NASDAQ:AMRN

Office

685 Third Avenue 26th Floor

10017 New York, New York

Phone (212) 983-9330

Fax (212) 983-9331

Counsel

Richard W. Gonnello rgonnello@faruqilaw.com Phone (212) 983-9330 Fax (212) 983-9331

Finding us

Our Offices


Our offices are nationwide. If you have any questions about a case or our firm, please contact us.

New York

685 Third Avenue 26th Floor
New York, New York 10017
(212) 983-9330
(877) 247-4292
(212) 983-9331

California

10866 Wilshire Boulevard Suite 1470
Los Angeles, California 90024
(424) 256-2884
(424) 256-2885

Delaware

3828 Kennett Pike Suite 201
Wilmington, Delaware 19807
(302) 482-3182
(302) 482-3612

Georgia

3975 Roswell Rd Suite A
Atlanta, Georgia 30342
(404) 847-0617
(404) 506-9534

Pennsylvania

1617 JFK Boulevard, Suite 1550
Philadelphia, Pennsylvania 19103
(215) 277-5770
(215) 277-5771

Faruqi & Faruqi office in New York, New York

Faruqi & Faruqi office in Los Angeles, California

Faruqi & Faruqi office in Wilmington, Delaware

Faruqi & Faruqi office in Atlanta, Georgia

Faruqi & Faruqi office in Philadelphia, Pennsylvania